Insights

  • Date

  • Content Type

  • Reset

Blog

Covid and consultancy – combating a global health crisis with unprecedented scientific and regulatory solutions

1.12.20

By Michael Pfleiderer

2020 certainly exceeded everybody’s expectations in any major area of everyday life and work. Read our leading vaccine...

Read More

Blog

Navigating the maze of environmental risk assessments for genetically modified products including ATMPs/CGTs

5.08.20

By Jörg Schneider


Environmental risk assessments (ERAs) for medicines containing genetically modified products are a prerequisite for clinical trial applications and...

Read More

Blog

Key features of the Voluntary Harmonisation Procedure (VHP)

7.06.20

By Liron Sarid-Krebs

The VHP allows simultaneous initiation of the clinical trial authorisation procedure in several European countries with a...

Read More

Blog

Recombinant viruses driving game-changing therapies

18.02.20

By Jörg Schneider

Recent years saw the approval of several Advanced Therapy Medicinal Products (ATMPs) using recombinant viruses and the pipeline...

Read More

Blog

Are biomarkers ushering a new era in vaccine discovery?

2.12.19

By Ilona Baraniak

Through many decades vaccines have helped us to control a wide range of pathogens. However, vaccine development...

Read More

Blog

Do We Need an EU Vaccine Regulation?

8.11.19

By Michael Pfleiderer

Neglected diseases, neglected vaccines. Unprecedented challenges, like the recurrence of known and new infectious diseases pose one...

Read More

We are now Cencora PharmaLex 

PharmaLex is now part of Cencora, a leading global healthcare company with a foundation in pharmaceutical distribution. In 2024 and beyond PharmaLex and all the companies in PharmaLex family will begin a journey to becoming Cencora as well. Cencora brings the companies and services together under one new name. The name will change, but the level of attention and service you receive remains the same.  

Know more